Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Veliparib [912444-00-9]
Katalog-Nummer T2591-10mg
Size : 10mg
Marke : TargetMol
Contact local distributor :
Telefonnummer : +1 850 650 7790
Veliparib
Catalog No. T2591 CAS 912444-00-9
Synonyms: ABT-888, NSC 737664
Veliparib (ABT-888) (ABT-888) is an orally bioavailable inhibitor of PARP (Kis: 5.2/2.9 nM for PARP1/2). It enhances apoptosis and autophagy.
All TargetMol products are for research or drug registration purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose in violation of laws and regulations.
Veliparib, CAS 912444-00-9
| Pack Size | /USD | |
|---|---|---|
| 5 mg | In stock | |
| 10 mg | In stock | |
| 25 mg | In stock | |
| 50 mg | In stock | |
| 100 mg | In stock | |
| 200 mg | In stock | |
| 500 mg | In stock | |
| 1 mL * 10 mM (in DMSO) | In stock |
Select Batch 
Purity: 99.76%
Purity: 99%
Purity: 98.92%
Contact us for more batch information
| Description | Veliparib (ABT-888) (ABT-888) is an orally bioavailable inhibitor of PARP (Kis: 5.2/2.9 nM for PARP1/2). It enhances apoptosis and autophagy. |
| Targets&IC50 | PARP2:2.9 nM (cell free), PARP1:5.2 nM (cell free) |
| In vitro | Veliparib (ABT-888) is a potent inhibitor of both PARP-1 and PARP-2 with K(i)s of 5.2 and 2.9 nmol/L, respectively [1]. In the HaCaT cell model, ABT-888 can reduce SM-induced NAD(+)/ATP depletion and apoptosis/necrosis [2]. ABT-888 reduced clonogenic survival in H460 lung cancer cells and inhibited DNA repair as shown by enhanced expression of DNA strand break marker histone gamma-H2AX [3]. |
| In vivo | PARP inhibition dramatically increased the efficacy of temozolomide at ABT-888 doses as low as 3.1 mg/kg/d and a maximal efficacy achieved at 25 mg/kg/d. In the MX-1 breast xenograft model (BRCA1 deletion and BRCA2 mutation), ABT-888 potentiated cisplatin, carboplatin, and cyclophosphamide, causing regression of established tumors, whereas, with comparable doses of cytotoxic agents alone, only modest tumor inhibition was exhibited [1]. ABT-888 increased tumor growth delay at well-tolerated doses in murine models. For a 5-fold increase in tumor volume, tumor growth delay was 1 day for ABT-888 alone, 7 days for radiation alone, and 13.5 days for combination treatment. A decrease in vitro endothelial tubule formation with ABT-888/radiation combination treatment and von Willebrand factor staining of tumor sections revealed decreased vessel formation in vivo [3]. |
| Kinase Assay | PARP assays were conducted in a buffer containing 50 mmol/L Tris (pH 8.0), 1 mmol/L DTT, 1.5 μmol/L [3H]NAD+ (1.6 μCi/mmol), 200 nmol/L biotinylated histone H1, 200 nmol/L slDNA, and 1 nmol/L PARP-1 or 4 nmol/L PARP-2 enzyme. Reactions were terminated with 1.5 mmol/L benzamide, transferred to streptavidin Flash plates, and counted using a TopCount microplate scintillation counter [1]. |
| Cell Research | Cell viability was quantified using the Cell Counting Kit-8 (CCK-8). This assay is based on Dojindo's highly water-soluble tetrazolium salt. WST-8 is reduced by dehydrogenases in cells to give an orange, water-soluble formazan dye. The amount of formazan dye generated by dehydrogenases in cells is directly proportional to the number of living cells. Briefly, exponentially growing HaCaT cells were seeded in 96-well plates at a density of 10,000 cells/well. 6 h or 24 h after exposure to SM and the administration of ABT-888, the CCK-8 reagent was added as recommended by the supplier [2]. |
| Animal Research | For oral pharmacokinetic studies, ABT-888 was separated from plasma and brain homogenate using liquid-liquid extraction with a mixture of ethyl acetate and hexane at alkaline pH. ABT-888 and the internal standard were separated from each other and coextracted contaminants on a 50 × 3 mm Keystone Betasil Cyano 5 μm C18 column with acetonitrile: 0.1% trifluoroacetic acid mobile phase (40:60, by volume) at a flow rate of 0.3 mL/min. Analysis was done on a Sciex API3000 Biomolecular Mass Analyzer with a turbo-ionspray interface using Sciex MacQuan software. The analysis of plasma pharmacokinetics from osmotic minipump (OMP) studies was conducted using acidified methanol precipitated plasma. Samples were injected onto a Phenomenex Synergi 4μ Polar RP column and ABT-888 eluted with a mixture of acetonitrile and 0.1% acetic acid in water at a flow rate of 0.4 mL/min. Mass analysis was done with a ThermoFinnigan LCQ Duo using Xcalibur software [1]. |
| Synonyms | ABT-888, NSC 737664 |
| Molecular Weight | 244.29 |
| Formula | C13H16N4O |
| CAS No. | 912444-00-9 |
Storage
Solubility Information
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 29 mg/mL(118.7 mM)
References and Literature
1. Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13(9):2728-37. 2. Liu F, et al. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo. PeerJ. 2016 Apr 4;4:e1890. 3. Albert JM, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 2007 May 15;13(10):3033-42. 4. Mao K, Chen J, Yu H, et al. Poly (ADP‐ribose) polymerase 1 inhibition prevents neurodegeneration and promotes α‐synuclein degradation via transcription factor EB‐dependent autophagy in mutant α‐synucleinA53T model of Parkinson's disease[J]. Aging Cell. 2020: e13163. 5. Epub 2020 May 31. PARP1 inhibition prevents neurodegeneration and promotes α-synuclein degradation via TFEB-dependent autophagy in mutant α-synucleinA53T model of Parkinson's disease. aging cell. 2020 Jun;19(6):e13163
Citations
1. Kanmin Mao,Jialong Chen,Honglin Yu,Huihui Li,Yixian Ren. Poly (ADP-ribose) polymerase 1 inhibition prevents neurodegeneration and promotes α-synuclein degradation via transcription factor EB-dependent autophagy in mutant α-synucleinA53T model of Parkinson's disease. Aging Cell. 2020 Jun;19(6):e13163 2. Epub 2020 May 31 PARP1 inhibition prevents neurodegeneration and promotes α-synuclein degradation via TFEB-dependent autophagy in mutant α-synucleinA53T model of Parkinson's disease. aging cell. 2020 Jun;19(6):e13163 3. Wang J, Xing W, Lin Y, et al. Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma. Journal of Clinical Laboratory Analysis. 2022: e24435 4. Liu C, Li J, Xu F, et al.PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.Molecular Cancer.2024, 23(1): 111.
Related compound libraries
This product is contained In the following compound libraries：
Anti-Cancer Clinical Compound Library Inhibitor Library Anti-Cancer Drug Library Anti-Cancer Active Compound Library Drug Repurposing Compound Library Highly Selective Inhibitor Library CNS-Penetrant Compound Library Anti-Cancer Compound Library Anti-Prostate Cancer Compound Library Anti-Liver Cancer Compound Library
Related Products
Related compounds with same targets
Dose Conversion
You can also refer to dose conversion for different animals. More
In vivo Formulation Calculator (Clear solution)
Step One: Enter information below
Dosage
mg/kg Average weight of animals
g Dosing volume per animal
ul Number of animals
Step Two: Enter the in vivo formulation
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL)，
Method for preparing in vivo formulation：Take μL DMSO master liquid, next add μL PEG300， mix and clarify, next add μL Tween 80，mix and clarify, next add μL ddH2O, mix and clarify.
Note:
Be sure to add the solvent(s) in order. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculator
bottom
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Keywords
Veliparib 912444-00-9 Autophagy Chromatin/Epigenetic DNA Damage/DNA Repair PARP ABT-888 inhibit Inhibitor NSC 737664 ABT 888 NSC737664 poly ADP ribose polymerase ABT888 NSC-737664 inhibitor